223 related articles for article (PubMed ID: 3018078)
21. Activation of the fifth and sixth components of the human complement system: C6-dependent cleavage of C5 in acid and the formation of a bimolecular lytic complex, C5b,6a.
Hammer CH; Hänsch G; Gresham HD; Shin ML
J Immunol; 1983 Aug; 131(2):892-8. PubMed ID: 6863934
[TBL] [Abstract][Full Text] [Related]
22. Implications for herpes simplex virus vaccine strategies based on antibodies produced to herpes simplex virus type 1 glycoprotein gC immune evasion domains.
Chang YJ; Jiang M; Lubinski JM; King RD; Friedman HM
Vaccine; 2005 Sep; 23(38):4658-65. PubMed ID: 15936852
[TBL] [Abstract][Full Text] [Related]
23. Herpes simplex virus glycoprotein C: molecular mimicry of complement regulatory proteins by a viral protein.
Huemer HP; Wang Y; Garred P; Koistinen V; Oppermann S
Immunology; 1993 Aug; 79(4):639-47. PubMed ID: 8406590
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
Sahu A; Kay BK; Lambris JD
J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942
[TBL] [Abstract][Full Text] [Related]
25. Complement activation by heat-killed human kidney cells: formation, activity, and stabilization of cell-bound C3 convertases.
Baker PJ; Adler S; Yang Y; Couser WG
J Immunol; 1984 Aug; 133(2):877-81. PubMed ID: 6376629
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of C3 deposition on solid-phase bound immune complexes by lactoferrin.
Kievits F; Kijlstra A
Immunology; 1985 Mar; 54(3):449-56. PubMed ID: 3844370
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.
Medof ME; Kinoshita T; Nussenzweig V
J Exp Med; 1984 Nov; 160(5):1558-78. PubMed ID: 6238120
[TBL] [Abstract][Full Text] [Related]
28. Secreted pH-regulated antigen 1 of Candida albicans blocks activation and conversion of complement C3.
Luo S; Hartmann A; Dahse HM; Skerka C; Zipfel PF
J Immunol; 2010 Aug; 185(4):2164-73. PubMed ID: 20644161
[TBL] [Abstract][Full Text] [Related]
29. Antibody restores human alternative complement pathway activation by mouse erythrocytes rendered functionally deficient by pretreatment with pronase.
Moore FD; Austen KF; Fearon DT
J Immunol; 1982 Mar; 128(3):1302-6. PubMed ID: 6915957
[TBL] [Abstract][Full Text] [Related]
30. The interaction of C5 with C3b in free solution: a sufficient condition for cleavage by a fluid phase C3/C5 convertase.
Isenman DE; Podack ER; Cooper NR
J Immunol; 1980 Jan; 124(1):326-31. PubMed ID: 7350230
[TBL] [Abstract][Full Text] [Related]
31. Human natural killer cell recognition of herpes simplex virus type 1 glycoproteins: specificity analysis with the use of monoclonal antibodies and antigenic variants.
Bishop GA; Marlin SD; Schwartz SA; Glorioso JC
J Immunol; 1984 Oct; 133(4):2206-14. PubMed ID: 6206157
[TBL] [Abstract][Full Text] [Related]
32. Complement component C3b binds directly to purified glycoprotein C of herpes simplex virus types 1 and 2.
Eisenberg RJ; Ponce de Leon M; Friedman HM; Fries LF; Frank MM; Hastings JC; Cohen GH
Microb Pathog; 1987 Dec; 3(6):423-35. PubMed ID: 2849025
[TBL] [Abstract][Full Text] [Related]
33. Novel mechanism of antibody-independent complement neutralization of herpes simplex virus type 1.
Friedman HM; Wang L; Pangburn MK; Lambris JD; Lubinski J
J Immunol; 2000 Oct; 165(8):4528-36. PubMed ID: 11035093
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of classical C5 convertase in the complement system by factor H.
Ito S; Tamura N
Immunology; 1983 Dec; 50(4):631-5. PubMed ID: 6228516
[TBL] [Abstract][Full Text] [Related]
35. The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb.
Fujita T; Inoue T; Ogawa K; Iida K; Tamura N
J Exp Med; 1987 Nov; 166(5):1221-8. PubMed ID: 2445886
[TBL] [Abstract][Full Text] [Related]
36. Glycoprotein C of herpes simplex virus type 1 is essential for the virus to evade antibody-independent complement-mediated virus inactivation and lysis of virus-infected cells.
Hidaka Y; Sakai Y; Toh Y; Mori R
J Gen Virol; 1991 Apr; 72 ( Pt 4)():915-21. PubMed ID: 1849974
[TBL] [Abstract][Full Text] [Related]
37. [Recent trends in complement research].
Inai S
Nihon Rinsho; 1983; 41(4):750-5. PubMed ID: 6350645
[No Abstract] [Full Text] [Related]
38. [Progress in the knowledge of complement. I. Structure, activation and control of the complement system].
Lesavre P; Leibowitch J
Nouv Presse Med; 1979 Jun; 8(29):2385-7. PubMed ID: 493022
[No Abstract] [Full Text] [Related]
39. Factor H binds to the N-terminus of adiponectin and modulates complement activation.
Peake P; Shen Y
Biochem Biophys Res Commun; 2010 Jun; 397(2):361-6. PubMed ID: 20513355
[TBL] [Abstract][Full Text] [Related]
40. Regulation of C5 convertase activity by properdin, factors B and H.
Weiler JM
Immunol Res; 1989; 8(4):305-15. PubMed ID: 2531781
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
